Get started
Author

Syota Sakaue

Observed name: Shota Sakaue
Observed institution: Asahikawa Medical University
ORCID: 0009-0002-1348-3331
Observed ORCID: 0009-0002-1348-3331
OpenAlex ID: A5134499120
Data from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 1 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 4 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 4 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 1 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Table 1 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 2 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 2 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 3 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 3 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Table 2 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Table 1 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 5 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al. · Cancer Research Communications
Distinct mechanisms of otitis media with effusion before/after treatment in nasopharyngeal carcinoma
2026 · Takumi Kumai, Syota Sakaue, et al. · Auris Nasus Larynx
Works count: 15
Citation count:
H-index:
I10-index:
Year
Topic
Type